JPH09140790A - Injection needle, chemicals to be stuck to injection needle, composition including the chemicals and production of the injection needle - Google Patents
Injection needle, chemicals to be stuck to injection needle, composition including the chemicals and production of the injection needleInfo
- Publication number
- JPH09140790A JPH09140790A JP7331243A JP33124395A JPH09140790A JP H09140790 A JPH09140790 A JP H09140790A JP 7331243 A JP7331243 A JP 7331243A JP 33124395 A JP33124395 A JP 33124395A JP H09140790 A JPH09140790 A JP H09140790A
- Authority
- JP
- Japan
- Prior art keywords
- injection needle
- drug
- chemicals
- squalene
- squalane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、注射針、注射針に
付着させる薬剤、その薬剤を含む組成物および注射針の
製造方法に関し、更に詳しくは注射針の切れ味を改良
し、刺通時の痛感を減少させるために、針の表面にスク
アレン、その部分水素添加物、スクアランまたはこれら
の混合物から選ばれる薬剤を付着させた注射針、注射針
に付着させるための薬剤、注射針に付着させるための薬
剤組成物、およびそのような注射針の製造方法に関する
ものである。TECHNICAL FIELD The present invention relates to an injection needle, a drug to be attached to the injection needle, a composition containing the drug, and a method for producing the injection needle. More specifically, the sharpness of the injection needle is improved to improve the sharpness at the time of piercing. In order to reduce the pain sensation, an injection needle to which a drug selected from squalene, its partial hydrogenation product, squalane or a mixture thereof is attached to the surface of the needle, a drug to be attached to the injection needle, to attach to the injection needle And a method for manufacturing such an injection needle.
【０００２】[0002]
【従来の技術】従来より、注射針の切れ味を改良して金
属製注射針の刺通時の痛感を減少させるなどのために
は、シリコーンオイルを塗布し針の表面にシリコーンの
被膜を形成することが広く行われている。2. Description of the Related Art Conventionally, in order to improve the sharpness of an injection needle and to reduce the sensation when a metal injection needle is pierced, silicone oil is applied to form a silicone coating on the surface of the needle. Is widely practiced.
【０００３】従来のシリコーンコーテイング剤は、シリ
コーン成分を有機溶媒で３０〜５０重量％程度に希釈し
た状態で市販され、使用時にこれをさらにｎ−ヘキサ
ン、フロン、イソプロパノール、塩素化炭化水素等の有
機溶媒で希釈して、シリコーン濃度が２〜５重量％程度
になるように調整し、注射針に塗布している。Conventional silicone coating agents are commercially available in the state where the silicone component is diluted with an organic solvent to the extent of 30 to 50% by weight. When used, the silicone coating agent is further added with organic materials such as n-hexane, freon, isopropanol and chlorinated hydrocarbons. It is diluted with a solvent, adjusted to have a silicone concentration of about 2 to 5% by weight, and applied to an injection needle.
【０００４】特公昭６２−５２７９６号公報には、アミ
ノ基含有シランとエポキシ基含有シランとの反応物と、
ポリジオルガノシロキサンとの反応生成物を不活性溶媒
に希釈したシリコーンコーテイング剤を塗布・硬化させ
ることにより、塗布表面の滑り性を向上させ得ることが
記載されている。Japanese Patent Publication No. 62-52796 discloses a reaction product of an amino group-containing silane and an epoxy group-containing silane.
It is described that the slipperiness of the coated surface can be improved by coating and curing a silicone coating agent obtained by diluting a reaction product with a polydiorganosiloxane in an inert solvent.
【０００５】また、特開平４−１５２９５３号公報に
は、塩化メチレンとメタノールの混合溶媒を希釈溶媒と
して、注射針の針管部にシリコーン含有溶液を塗布して
乾燥させ、針管表面にシリコーンの薄い被膜を形成させ
る方法が記載されている。Further, in Japanese Unexamined Patent Publication (Kokai) No. 152953/1992, a silicone-containing solution is applied to a needle tube portion of an injection needle and dried by using a mixed solvent of methylene chloride and methanol as a diluting solvent, and a thin silicone film is formed on the surface of the needle tube. A method of forming a is described.
【０００６】しかしながら、上述したシリコーンをコー
テイング剤として用いる方法においては、シリコーンオ
イル自体は生理的に不活性であり毒性はないものの、針
に付着した液状低分子シリコーンが針の刺通とともに体
内に侵入、残留する可能性があり、その結果体内に蓄積
するような場合、シリコーンが生体発生物ではないので
人体に悪影響を及ぼす危険性が全くない訳ではない。そ
のほか、たとえば、血管内に微小エマルジョンとして侵
入したとき、末梢の毛細管を閉塞させる危険も有り得
る。However, in the above-mentioned method of using silicone as a coating agent, although the silicone oil itself is physiologically inactive and not toxic, the liquid low-molecular-weight silicone adhering to the needle penetrates into the body as the needle pierces. When there is a possibility that it may remain and accumulate in the body as a result, silicone is not a biological product, so there is a risk of adversely affecting the human body. In addition, there is a risk of occluding the peripheral capillaries, for example, when entering the blood vessel as a microemulsion.
【０００７】[0007]
【発明が解決しようとする課題】本発明は、人体に影響
のより少ない生体適合性のある物質を注射針に付着さ
せ、刺通時の痛感を減少させ得る注射針を提供するもの
であり、また注射針に付着させるための薬剤、注射針に
この薬剤を付着させるための薬剤組成物、およびそのよ
うな注射針の製造方法を提供するものである。DISCLOSURE OF THE INVENTION The present invention provides an injection needle capable of reducing a pain sensation at the time of piercing by attaching a biocompatible substance having less influence on the human body to the injection needle. The present invention also provides a drug for adhering to the injection needle, a pharmaceutical composition for adhering this drug to the injection needle, and a method for producing such an injection needle.
【０００８】[0008]
【課題を解決するための手段】本発明者は、従来におけ
るシリコーンオイルの欠点を除くために種々研究の結
果、体内に残留しても蓄積せず生体適合性のある特定の
物質を注射針に付着させることにより、人体に悪影響を
及ぼす危険性を排除でき、課題を解決できることを見い
だし、本発明を成すに至った。As a result of various studies to eliminate the drawbacks of conventional silicone oils, the present inventor has found that a specific biocompatible substance, which does not accumulate even if it remains in the body, is used as an injection needle. It was found that the risk of adversely affecting the human body can be eliminated and the problem can be solved by the attachment, and the present invention has been accomplished.
【０００９】本発明の請求項１の発明は、少なくとも先
端部の表面にスクアレン、その部分水素添加物、スクア
ランおよびこれらの混合物から成る群から選ばれる少な
くとも一つの薬剤を付着させたことを特徴とする人体ま
たは動物用注射針である。The invention of claim 1 of the present invention is characterized in that at least one agent selected from the group consisting of squalene, a partial hydrogenated product thereof, squalane and a mixture thereof is attached to at least the surface of the tip. It is a human or animal injection needle.
【００１０】本発明の請求項２の発明は、人体または動
物用注射針の少なくとも先端部の表面に付着させるため
の薬剤であって、スクアレン、その部分水素添加物、ス
クアランおよびこれらの混合物から成る群から選ばれる
少なくとも一つの薬剤である。A second aspect of the present invention is a drug for adhering to at least the surface of the tip of a human or animal injection needle, which comprises squalene, a partial hydrogenation product thereof, squalane and a mixture thereof. At least one drug selected from the group.
【００１１】本発明の請求項３の発明は、人体または動
物用注射針の少なくとも先端部の表面に請求項２記載の
薬剤を付着させるための薬剤組成物であって、請求項２
記載の薬剤、およびこの薬剤を含浸させるための基材あ
るいはこの薬剤を希釈するための溶媒から成ることを特
徴とする薬剤組成物である。The invention of claim 3 of the present invention is a pharmaceutical composition for adhering the drug of claim 2 to the surface of at least the tip of a human or animal injection needle.
A drug composition comprising the drug described above and a base material for impregnating the drug or a solvent for diluting the drug.
【００１２】本発明の請求項４の発明は、請求項２記載
の薬剤および／または請求項３記載の薬剤組成物を人体
または動物用注射針の少なくとも先端部の表面に適用し
て請求項２記載の薬剤を付着させることを特徴とする請
求項１記載の注射針の製造方法である。以下、本発明を
さらに詳細に説明する。The invention according to claim 4 of the present invention comprises applying the drug according to claim 2 and / or the drug composition according to claim 3 to at least the surface of the tip of a human or animal injection needle. The method for producing an injection needle according to claim 1, characterized in that the agent described above is attached. Hereinafter, the present invention will be described in more detail.
【００１３】[0013]
【発明の実施の形態】本発明でいうスクアレンとはオリ
ーブ油、米ぬか油、トウモロコシ油などの植物油および
鶏肉、豚肉、一般魚類などの動物油など各種動植物原料
ならびに人体にも微量含まれているが、最も多くは深海
鮫肝油に含有されている多不飽和化合物としての炭化水
素化合物である。イソプレン等から合成される合成スク
アレンも使用し得るが、好ましくは動植物由来の天然ス
クアレンである。BEST MODE FOR CARRYING OUT THE INVENTION Squalene as used in the present invention is contained in trace amounts in various animal and plant raw materials such as vegetable oils such as olive oil, rice bran oil and corn oil and animal oils such as chicken, pork and general fish, as well as the human body. Most are hydrocarbon compounds as polyunsaturated compounds contained in deep sea shark liver oil. Although synthetic squalene synthesized from isoprene or the like can be used, natural squalene derived from animals and plants is preferable.
【００１４】本発明でいうスクアランは、スクアレン、
好ましくは天然スクアレンの全ての不飽和結合を水素添
加してなるスクアレンの完全水素化物である。生体内か
らもスクアランは見いだされており、スクアレン同様ス
クアランもまた生体反応生成物とみなし得るといわれて
いる。The squalane referred to in the present invention is squalene,
Preferred is a fully hydrogenated squalene obtained by hydrogenating all unsaturated bonds of natural squalene. Squalane has been found in vivo, and it is said that squalane, like squalene, can also be regarded as a biological reaction product.
【００１５】また、本発明ではスクアレン、好ましくは
天然スクアレンの部分水素添加物も用いることができ
る。これらは、適宜に混合して用いることができる。な
お、水素添加は、白金、プラチナ、コバルト、モリブデ
ン、ニッケルまたはこれらの混合物からなる金属触媒に
より常法に従い水素添加することにより行うことができ
る。ヨウ素価（ｇ／１００ｇ）が３．５以下のものは、
酸化安定性が高く好ましい。In the present invention, a partially hydrogenated product of squalene, preferably natural squalene can also be used. These can be appropriately mixed and used. The hydrogenation can be carried out by hydrogenation according to a conventional method using a metal catalyst composed of platinum, platinum, cobalt, molybdenum, nickel or a mixture thereof. If the iodine value (g / 100g) is 3.5 or less,
It is preferable because it has high oxidative stability.
【００１６】またこれらスクアレンやスクアランは、体
内では速やかに吸収されるといわれている。したがっ
て、スクアレン、スクアラン等が血管内に混入しても速
やかに体内に吸収されるので人体に悪影響を及ぼす危険
性を排除できる。Further, these squalene and squalane are said to be rapidly absorbed in the body. Therefore, even if squalene, squalane, etc. are mixed in the blood vessel, they are quickly absorbed in the body, and the risk of adversely affecting the human body can be eliminated.
【００１７】本発明においては、人体または動物用注射
針の少なくとも先端部の表面にスクアレン、その部分水
素添加物、スクアランおよびこれらの混合物から成る群
から選ばれる少なくとも一つの薬剤を付着させるが、こ
の薬剤には従来公知の酸化防止剤、たとえばビタミン
Ｅ、レシチン等をさらに適宜に配合して用いることがで
きる。そのほか、本発明の効果を奏する限り、水素添加
されたオレフィンオリゴマー、たとえばエチレン、プロ
ピレン、イソブチレン、デセンのオリゴマーの水素添加
物等を粘度調整剤や増量剤などとしてさらに配合するこ
とができる。なお酸化防止剤を初めとし、これら添加剤
はいずれも油溶性の添加剤が好ましい。In the present invention, at least one drug selected from the group consisting of squalene, its partial hydrogenated product, squalane and mixtures thereof is attached to the surface of at least the tip of a human or animal injection needle. Conventionally known antioxidants such as vitamin E and lecithin can be appropriately blended and used as the drug. In addition, a hydrogenated olefin oligomer, for example, a hydrogenated product of an oligomer of ethylene, propylene, isobutylene, or decene may be further added as a viscosity modifier or a bulking agent as long as the effects of the present invention are exhibited. It is to be noted that all of these additives including an antioxidant are preferably oil-soluble additives.
【００１８】スクアレン、その部分水素添加物、スクア
ランまたはこれらの混合物は、注射針の少なくとも先端
部に付着させる。注射針は、人体または動物用注射針の
注射針であれば特に限定されない。たとえば人体用の注
射針としては、筋肉注射用針、静脈注射用針、点滴や輸
血用の留置針などが例示される。これらは、通常ステン
レススチールなどの金属製である。針の金属表面にはシ
リコーン硬化膜などの樹脂膜が形成されていてもよい。Squalene, its partial hydrogenation, squalane or mixtures thereof is applied to at least the tip of the injection needle. The injection needle is not particularly limited as long as it is a human or animal injection needle. Examples of the injection needle for the human body include an intramuscular injection needle, an intravenous injection needle, an indwelling needle for infusion and blood transfusion, and the like. These are usually made of metal such as stainless steel. A resin film such as a silicone cured film may be formed on the metal surface of the needle.
【００１９】スクアレン、その部分水素添加物、スクア
ランまたはこれらの混合物の付着量は有効量であればよ
いが、たとえば、注射針の先端部の単位表面積（１ｍｍ
2 ）当たり０．０００３μｇ〜１０，０００μｇの範囲
である。多すぎては油滴となるのでこの範囲内ならば有
効に本発明の効果が発揮され、また経済的でもある。The amount of squalene, its partial hydrogenated product, squalane or a mixture thereof may be any effective amount. For example, the unit surface area of the tip of the injection needle (1 mm
2 ) The range is 0.0003 μg to 10,000 μg. If the amount is too large, oil droplets are formed, so that the effect of the present invention is effectively exhibited within this range, and it is also economical.
【００２０】ここで、注射針の先端部とは針先より２０
ｍｍ以内、好ましくは１０ｍｍ以内、さらに好ましくは
５ｍｍ以内の部分のことをいう。スクアレン、その部分
水素添加物、スクアランまたはこれらの混合物は、注射
針の先端部のみに付着させてもよいし、先端部を含む注
射針全体に付着させてもよい。Here, the tip of the injection needle is 20 from the tip of the needle.
It is a portion within mm, preferably within 10 mm, and more preferably within 5 mm. Squalene, its partial hydrogenation product, squalane, or a mixture thereof may be attached only to the tip of the injection needle, or may be attached to the entire injection needle including the injection tip.
【００２１】本発明においては、注射針の少なくとも先
端部の表面に本発明の薬剤を付着させる方法は特に限定
されない。本発明の薬剤自体を使用して注射針に適用し
てもよいが、本発明の薬剤とこの薬剤を含浸させるため
の脱脂綿などの綿または布などの基材から成る薬剤組成
物を使用して注射針に適用してもよく、また、本発明の
薬剤を溶媒で希釈した薬剤組成物を使用して注射針に適
用してもよい。In the present invention, the method of attaching the drug of the present invention to at least the surface of the tip of the injection needle is not particularly limited. Although the drug of the present invention itself may be applied to an injection needle, a drug composition comprising the drug of the present invention and a base material such as cotton or cloth such as absorbent cotton for impregnating the drug is used. It may be applied to an injection needle, or may be applied to an injection needle using a drug composition obtained by diluting the drug of the present invention with a solvent.
【００２２】本発明の薬剤組成物には上記のような従来
公知の酸化防止剤、たとえばビタミンＥ、レシチン等を
さらに適宜に配合して用いることができる。そのほか、
本発明の効果を奏する限り、水素添加されたオレフィン
オリゴマー、たとえばエチレン、プロピレン、イソブチ
レン、デセンのオリゴマーの水素添加物等を粘度調整剤
や増量剤などとしてさらに配合することができる。The above-mentioned conventionally known antioxidants such as vitamin E, lecithin and the like can be further appropriately blended and used in the pharmaceutical composition of the present invention. others,
As long as the effects of the present invention are exhibited, a hydrogenated olefin oligomer, for example, a hydrogenated product of an oligomer of ethylene, propylene, isobutylene, or decene can be further added as a viscosity modifier or a bulking agent.
【００２３】注射針の少なくとも先端部の表面に本発明
の薬剤を付着させる方法は、たとえば、具体的には、ス
クアレン、その部分水素添加物、スクアランまたはこれ
らの混合物を適宜の有機溶媒に希釈して噴霧、浸漬もし
くは塗布した後、室温あるいは加温下に放置して溶媒を
蒸発させ、被膜を形成させる方法が一般的である。希釈
濃度は０．１〜３０重量％、好ましくは１〜２０重量％
である。もちろん、希釈することなく、そのまま用いて
噴霧、浸漬、塗布することも可能である。そのほか、た
とえば脱脂綿などの綿または布に湿潤させ、これに針を
適宜に通すことにより付着させる方法を採用することも
できる。The method of attaching the drug of the present invention to the surface of at least the tip of the injection needle is, for example, specifically, squalene, its partial hydrogenated product, squalane or a mixture thereof is diluted with an appropriate organic solvent. After spraying, dipping or coating, the solvent is evaporated at room temperature or under heating to form a film. Dilution concentration is 0.1 to 30% by weight, preferably 1 to 20% by weight
It is. Of course, it is also possible to spray, dip, or apply the powder as it is without diluting it. In addition, it is also possible to adopt a method in which, for example, a cotton or cloth such as absorbent cotton is moistened, and a needle is appropriately passed through this to adhere the cotton or cloth.
【００２４】希釈する場合の有機溶媒としては、プロピ
レン、プロパン、ブタンガス、ＬＰＧ、石油エーテル、
ホワイトガソリン、ｎ−ペンタン、ｎ−ヘキサン、シク
ロヘキサン、ｎ−ヘプタン、ｎ−オクタン、イソオクタ
ン、ベンゼン、トルエン、キシレン、エチルベンゼン等
の脂肪族、脂環族、芳香族炭化水素またはこれらの混合
物；塩化メチレン、クロロホルム等の各種の塩素化炭化
水素等；トリクロロフルオロメタン、１，１，２−トリ
クロロ−１，２，２−トリフルオロエタン等のフロン系
溶剤等が用いられる。これらは混合して用いることもで
きる。沸点としては好ましくは１８０℃以下、さらに好
ましくは１５０℃以下の沸点の有機溶媒である。有機溶
媒は、使用前には適宜にこれを蒸発させる。蒸発には要
すれば加熱するが、加熱する場合には２００℃以下の温
度で行うのが好ましい。As the organic solvent for dilution, propylene, propane, butane gas, LPG, petroleum ether,
White gasoline, n-pentane, n-hexane, cyclohexane, n-heptane, n-octane, isooctane, benzene, toluene, xylene, ethylbenzene and other aliphatic, alicyclic, aromatic hydrocarbons or mixtures thereof; methylene chloride , Various kinds of chlorinated hydrocarbons such as chloroform; and freon solvents such as trichlorofluoromethane and 1,1,2-trichloro-1,2,2-trifluoroethane. These can be used as a mixture. An organic solvent having a boiling point of preferably 180 ° C. or lower, more preferably 150 ° C. or lower. The organic solvent is appropriately evaporated before use. The evaporation is heated if necessary, but the heating is preferably performed at a temperature of 200 ° C. or lower.
【００２５】上述の方法により、スクアレン、その部分
水素添加物、スクアランまたはこれらの混合物を注射針
に付着後、要すれば包装をし、滅菌をする。滅菌方法と
しては、公知のいずれの方法も採用することができる。
たとえば、ガンマ線照射による滅菌方法を採用すること
ができる。According to the above-mentioned method, squalene, its partially hydrogenated product, squalane or a mixture thereof is attached to an injection needle, and if necessary, packaged and sterilized. As a sterilization method, any known method can be adopted.
For example, a sterilization method by gamma ray irradiation can be adopted.
【００２６】本発明においては、上記のように本発明の
薬剤や本発明の薬剤組成物を注射針の少なくとも先端部
の表面に適用して本発明の薬剤を付着させた注射針を用
いて人体または動物に注射するが、注射する際に本発明
の薬剤をあらかじめ付着させた注射針を用いてもよい
が、勿論、あらかじめ殺菌済みのスクアレン等を用い、
使用直前に付着させて用いることも可能である。In the present invention, as described above, the drug of the present invention or the drug composition of the present invention is applied to at least the surface of the tip of the injection needle, and the injection needle to which the drug of the present invention is adhered is used for the human body. Alternatively, it is injected into an animal, and the injection needle to which the drug of the present invention is pre-attached may be used at the time of injection, but of course, pre-sterilized squalene or the like is used,
It is also possible to attach and use it just before use.
【００２７】[0027]
【実施例】以下に実施例を示して本発明をさらに具体的
に説明するが、本発明はこれらの実施例に限定されるも
のではない。 （実施例１）深海鮫肝油から採取したスクアレンを常法
により完全水素添加して得られた純度９９．５％、ヨウ
素価０．０１のスクアランを殺菌済みの脱脂綿に浸し
た。人体の筋肉注射用注射針を上記の脱脂綿に刺してス
クアランを付着させた。付着量は、約０．０１μｇ（１
ｍｍ2 当たり）であった。The present invention will be described in more detail with reference to the following examples, but the present invention is not limited to these examples. Example 1 Squalene having a purity of 99.5% and an iodine value of 0.01, which was obtained by completely hydrogenating squalene collected from deep-sea shark liver oil by a conventional method, was dipped in sterilized absorbent cotton. An injection needle for intramuscular injection of a human body was stabbed into the absorbent cotton to attach squalane. The amount deposited is about 0.01 μg (1
(per mm 2 ).
【００２８】（実施例２）深海鮫肝油から採取したスク
アレンを常法により完全水素添加した純度９９．４％、
ヨウ素価０．６のスクアランを、ブタンガスで希釈して
２重量％の希釈スクアランを調整し、これをボンベに充
填した。得られたボンベをステンレススチール製注射針
（人体の筋肉注射用注射針）の先端部に噴霧した後、乾
燥させることにより注射針の先端より１０ｍｍの範囲に
約０．０１μｇ（１ｍｍ2 当たり）のスクアランを付着
させた。Example 2 Squalene collected from deep-sea shark liver oil was completely hydrogenated by a conventional method to obtain a purity of 99.4%.
Squalane having an iodine value of 0.6 was diluted with butane gas to prepare a diluted squalane of 2% by weight, and this was filled in a cylinder. The obtained cylinder was sprayed onto the tip of a stainless steel injection needle (injection needle for intramuscular injection in the human body) and then dried to obtain about 0.01 μg (per 1 mm 2 ) within 10 mm from the tip of the injection needle. Squalane was applied.
【００２９】（実施例３）オリーブ油から採取された天
然スクアレンを常法により完全水素添加して得られた天
然スクアラン（ヨウ素価 １．８、純度９４．５％）
を、塩化メチレンに希釈し、濃度５重量％の希釈液を得
た。この希釈液をスプレーで筋肉注射用注射針に噴霧
後、室内に放置して乾燥させた。これにより注射針の先
端より１０ｍｍの範囲に約０．０１μｇ（１ｍｍ2 当た
り）のスクアランを付着させた。(Example 3) Natural squalene obtained by complete hydrogenation of natural squalene collected from olive oil by a conventional method (iodine value 1.8, purity 94.5%)
Was diluted with methylene chloride to obtain a diluted solution having a concentration of 5% by weight. The diluted solution was sprayed onto an intramuscular injection needle and then left indoors to dry. As a result, about 0.01 μg (per 1 mm 2 ) of squalane was deposited within a range of 10 mm from the tip of the injection needle.
【００３０】（実施例４）深海鮫肝油から採取された天
然スクアレン［過酸化物価（ＰＯＶ）＝０．１、純度９
９．８％］を、塩化メチレンに希釈し、濃度５重量％の
希釈液を得た。この希釈液をスプレーで筋肉注射用注射
針に噴霧後、室内に放置して乾燥させた。これにより注
射針の先端より１０ｍｍの範囲に約０．００１μｍｇ
（１ｍｍ2 当たり）のスクアレンを付着させた。(Example 4) Natural squalene collected from deep-sea shark liver oil [peroxide value (POV) = 0.1, purity 9]
9.8%] was diluted with methylene chloride to obtain a diluted solution having a concentration of 5% by weight. The diluted solution was sprayed onto an intramuscular injection needle and then left indoors to dry. As a result, about 0.001 μmg within 10 mm from the tip of the injection needle
Squalene (per 1 mm 2 ) was deposited.
【００３１】（試験）次に、実施例１で得られた注射針
および無処理の同種の注射針を用いて、１人にそれぞれ
注射し、異なる２本の針間の痛感を各人に比較させた。
また同時に出血の程度も目視により比較観察した。試験
に際しては被試験者には２種の針の種別は教えず、また
付着がわずかなこともあり単なる目視による観察では２
種の針の区別はつかない。痛感、止血の試験結果をそれ
ぞれ表１および表２に示した。試験結果は、表１および
表２に示すように、一方の針に比較しより痛感を感じた
人数、および出血を見た人数で表した。試験人数は、成
人男女合わせて計１０名である。(Test) Next, using the injection needle obtained in Example 1 and a non-treated injection needle of the same kind, one person was injected with each, and the pain feeling between two different needles was compared with each other. Let
At the same time, the degree of bleeding was also visually compared and observed. At the time of the test, the test subject was not informed of the types of the two types of needles, and the adhesion was slight, so it was 2
The needles of the species cannot be distinguished. The test results for pain and hemostasis are shown in Table 1 and Table 2, respectively. As shown in Tables 1 and 2, the test results were expressed by the number of people who felt more painful than one needle and the number of people who saw bleeding. The total number of test persons is 10 for both adults and men.
【００３２】[0032]
【表１】 [Table 1]
【００３３】[0033]
【表２】 [Table 2]
【００３４】表１および表２の結果から明かなように、
本発明のスクアランを付着させた注射針は痛感を減少さ
せ、良好な止血効果を示した。As is clear from the results of Tables 1 and 2,
The injection needle to which squalane of the present invention was attached reduced pain and showed good hemostatic effect.
【００３５】[0035]
【発明の効果】本発明のスクアレン、その部分水素化
物、スクアランまたはこれらの混合物を付着させた注射
針を用いることにより、刺通時の痛感を減少し、優れた
切れ味の注射針を得ることができる。さらに、スクアレ
ンやスクアランは生体反応生成物であるので、人体に悪
影響を及ぼす危険性がない。また、スクアレン、その部
分水素化物、スクアランまたはこれらの混合物が付着し
た針を用いることにより、止血効果も期待され、有用な
注射針を提供できる。また注射針に付着させるためのス
クアレン、その部分水素化物、スクアランまたはこれら
の混合物から成る本発明の薬剤、あるいは注射針に付着
させるための本発明の薬剤組成物を用いれば注射針にあ
らかじめ付着させておくことも、あるいは注射の直前に
注射針に付着させて使用することもできる。By using the injection needle to which the squalene of the present invention, its partial hydride, squalane, or a mixture thereof is attached, it is possible to reduce the pain sensation during piercing and obtain an injection needle with excellent sharpness. it can. Furthermore, since squalene and squalane are biological reaction products, there is no risk of adversely affecting the human body. Further, by using a needle to which squalene, a partial hydride thereof, squalane or a mixture thereof is attached, a hemostatic effect is expected and a useful injection needle can be provided. Moreover, when squalene for adhering to an injection needle, a partial hydride thereof, squalane or a drug of the present invention consisting of a mixture thereof, or a pharmaceutical composition of the present invention for adhering to an injection needle is used, it is preliminarily applied to an injection needle. It can be stored in advance, or it can be used by being attached to the injection needle immediately before injection.
Claims (4)
その部分水素添加物、スクアランおよびこれらの混合物
から成る群から選ばれる少なくとも一つの薬剤を付着さ
せたことを特徴とする人体または動物用注射針。1. Squalene on at least the surface of the tip,
An injection needle for a human body or an animal, to which at least one drug selected from the group consisting of the partially hydrogenated product, squalane and a mixture thereof is attached.
端部の表面に付着させるための薬剤であって、スクアレ
ン、その部分水素添加物、スクアランおよびこれらの混
合物から成る群から選ばれる少なくとも一つの薬剤。2. A drug for adhering to the surface of at least the tip of a human or animal injection needle, which is at least one drug selected from the group consisting of squalene, its partial hydrogenated product, squalane and mixtures thereof. .
端部の表面に請求項２記載の薬剤を付着させるための薬
剤組成物であって、請求項２記載の薬剤、およびこの薬
剤を含浸させるための基材あるいはこの薬剤を希釈する
ための溶媒から成ることを特徴とする薬剤組成物。3. A pharmaceutical composition for adhering the drug according to claim 2 to at least the surface of the tip of a human or animal injection needle, wherein the drug according to claim 2 and for impregnating the drug. And a solvent for diluting the drug.
項３記載の薬剤組成物を人体または動物用注射針の少な
くとも先端部の表面に適用して請求項２記載の薬剤を付
着させることを特徴とする請求項１記載の注射針の製造
方法。4. Applying the drug according to claim 2 and / or the drug composition according to claim 3 to at least the surface of the tip of a human or animal injection needle to attach the drug according to claim 2. The method for manufacturing an injection needle according to claim 1, which is characterized in that.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7331243A JPH09140790A (en) | 1995-11-28 | 1995-11-28 | Injection needle, chemicals to be stuck to injection needle, composition including the chemicals and production of the injection needle |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7331243A JPH09140790A (en) | 1995-11-28 | 1995-11-28 | Injection needle, chemicals to be stuck to injection needle, composition including the chemicals and production of the injection needle |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH09140790A true JPH09140790A (en) | 1997-06-03 |
Family
ID=18241506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP7331243A Pending JPH09140790A (en) | 1995-11-28 | 1995-11-28 | Injection needle, chemicals to be stuck to injection needle, composition including the chemicals and production of the injection needle |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH09140790A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0947491A1 (en) * | 1998-04-01 | 1999-10-06 | Nippon Petrochemicals Company, Limited | Highly pure squalane, raw material for pharmaceuticals and cosmetics prepared by using the same and method for producing the same |
| US6165481A (en) * | 1997-12-25 | 2000-12-26 | Nippon Petrochemicals Company, Inc. | Highly pure squalane, raw material for pharmaceuticals and cosmetics prepared by using the same and method for producing the same |
| JP2011067232A (en) * | 2009-09-24 | 2011-04-07 | Kawasumi Lab Inc | Medical needle |
-
1995
- 1995-11-28 JP JP7331243A patent/JPH09140790A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6165481A (en) * | 1997-12-25 | 2000-12-26 | Nippon Petrochemicals Company, Inc. | Highly pure squalane, raw material for pharmaceuticals and cosmetics prepared by using the same and method for producing the same |
| EP0947491A1 (en) * | 1998-04-01 | 1999-10-06 | Nippon Petrochemicals Company, Limited | Highly pure squalane, raw material for pharmaceuticals and cosmetics prepared by using the same and method for producing the same |
| JP2011067232A (en) * | 2009-09-24 | 2011-04-07 | Kawasumi Lab Inc | Medical needle |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4784842A (en) | Therapeutic composition for treatment of cuts, burns and abrasions | |
| Lis‐Balchin et al. | Relationship between bioactivity and chemical composition of commercial essential oils | |
| JP4974015B2 (en) | Brain mental stabilization material with fir tree extract | |
| US6656167B2 (en) | Piercing needle | |
| Lis-Balchin et al. | Comparison of the pharmacological and antimicrobial action of commercial plant essential oils | |
| Drachman | Is acetylcholine the trophic neuromuscular transmitter? | |
| EP0973504B1 (en) | Hemostatic aerosol composition | |
| JP2003138290A (en) | Perfume composition having mosquito repellent effect | |
| Hermans | Results of a survey on the use of different treatment options for partial and full thickness burns | |
| CN110035735A (en) | Water-In-Oil foam comprising betulin and combinations thereof | |
| Messina et al. | Microcirculatory effects of prostaglandins E1, E2, and A1 in the rat mesentery and cremaster muscle | |
| JPH09140790A (en) | Injection needle, chemicals to be stuck to injection needle, composition including the chemicals and production of the injection needle | |
| EP0956305A1 (en) | Cellulose derivatives | |
| RU2031661C1 (en) | Agent for treatment of wounds and for rendering first medical aid | |
| US3069319A (en) | Sprayable composition | |
| CN113769024B (en) | Compound essential oil for improving mood and preparation method and application thereof | |
| Stefano et al. | Methionine enkephalin inhibits the bursting activity of the Br-type neuron in Helix pomatia L. | |
| Krivoy | Potentiation of substance P by lysergic acid diethylamide in vivo | |
| WO2011040432A1 (en) | Eye wash agent | |
| JP2016150936A (en) | Supplements for sleep | |
| Porjesz et al. | The effects of alcohol on the somatosensory evoked potentials in man | |
| Besson et al. | Effects of gamma-hydroxybutyrate on segmental and cortical control of transmission of the afferent volley at spinal level | |
| JPH05221804A (en) | Insect pest-capturing agent composition | |
| JPH09164204A (en) | Lubricative agent for syringe and syringe using the same | |
| JPH07328108A (en) | Organic tissue adhesive and blood coagulant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20040302 |